Storia in 2 fonti

Tata-backed MedTherapy claims CAR-T breakthrough with one-day production

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can reduce production time from several weeks to just one day and cut costs by nearly 70%, potentially making advanced cancer treatment more affordable.

Raccontata da

thehindubusinessline.com

economictimes.indiatimes.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo3 mesi fa

Tata-backed MedTherapy claims CAR-T breakthrough with one-day production

originale

thehindubusinessline.com3 mesi fa

Tata Sons-funded MedTherapy brings contract model for cell and gene therapy to India

MedTherapy was founded in the US in 2018 and incorporated in India in 2020, he said, and pointed to support from the late Ratan Tata in helping bring breakthrough therapies (especially for cancer) to India

Timeline cronologica

mercoledì 27 maggio 2026·thehindubusinessline.com
Tata Sons-funded MedTherapy brings contract model for cell and gene therapy to India
MedTherapy was founded in the US in 2018 and incorporated in India in 2020, he said, and pointed to support from the late Ratan Tata in helping bring breakthrough therapies…
mercoledì 27 maggio 2026·economictimes.indiatimes.com
Tata-backed MedTherapy claims CAR-T breakthrough with one-day production
Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can reduce production time from several weeks to…